List of Orenitram drug patents

Orenitram is owned by United Therap.

Orenitram contains Treprostinil Diolamine.

Orenitram has a total of 13 drug patents out of which 0 drug patents have expired.

Orenitram was authorised for market use on 20 December, 2013.

Orenitram is available in tablet, extended release;oral dosage forms.

Orenitram can be used as use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1)., method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically acceptable salt of treprostinil, a method of treating pulmonary hypertension and pulmonary arterial hypertension by administering an oral osmotic pharmaceutical dosage form; a method of oral delivery of treprostinil comprising administering an oral osmotic pharmaceutical dosage form.

The generics of Orenitram are possible to be released after 11 August, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9050311 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US7417070 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Jul, 2026

(3 years from now)

US8497393 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9422223 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US9278901 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US8252839 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US7544713 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Jul, 2024

(1 year, 5 months from now)

US9393203 UNITED THERAP Osmotic drug delivery system
Apr, 2026

(3 years from now)

US8410169 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Feb, 2030

(7 years from now)

US8349892 UNITED THERAP Solid formulations of prostacyclin analogs
Jan, 2031

(7 years from now)

US8747897 UNITED THERAP Osmotic drug delivery system
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 18, 2022
Orphan Drug Exclusivity (ODE) Oct 18, 2026

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Market Authorisation Date: 20 December, 2013

Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).; Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically acceptable salt of treprostinil; A method of treating pulmonary hypertension and pulmonary arterial hypertension by administering an oral osmotic pharmaceutical dosage form; A method of oral delivery of treprostinil comprising administering an oral osmotic pharmaceutical dosage form

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ORENITRAM before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in